CVRx, Inc. develops an implantable technology for the treatment of high blood pressure/hypertension and heart failure patients. It offers BAROSTIM NEO, a neuro-modulation therapy that triggers the body''s natural reflex to regulate blood pressure and the underlying causes of the progression of heart failure, which is delivered through a long-lasting implant system, and customized to each patient''s individual therapy needs. The company serves patients and healthcare professionals. CVRx, Inc. was incorporated in 2000 and is based in Minneapolis, Minnesota. It has operations in the United States, the United Kingdom, the Netherlands, Italy, Germany, and internationally. Najnowsze artykuły o akcjach